A Phase 1 interventional study of Trastuzumab deruxtecan and Nivolumab in Breast Cancer and Urothelial Carcinoma, sponsored by Daiichi Sankyo. Completed at 29 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-27.
Sponsored by Daiichi Sankyo · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.
Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 36th largest by enrollment, is one of 6 that started in 2018, is one of 6 in phase 1, and was the 6th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
SOLTI Breast Cancer Research Group · Sites in France, Germany, Spain
Ages 18+
Kristina A. Fanucci · Sites in United States
Ages 18+
Institut Claudius Regaud · Sites in France
Ages 18+
By country, each count listing its studies:
trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab deruxtecan is the treatment under test here. Read study by study →
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 37 · Phase 3 12 · Phase 4 2
First in 2017; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 139 across the 58 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 58 have an industry lead sponsor. The 10 most frequent:
Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 37 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.
24 studies in Breast Neoplasms by Daiichi Sankyo: 6 open now, 8 under way, 3 of them phase 3. Of 16 finished, 8 (50%) have results posted.
Among the 24 studies in Breast Neoplasms by Daiichi Sankyo, this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2018, is one of 4 in phase 1, and was the 9th registered.
Daiichi Sankyo’s Breast Neoplasms studies by the year they started, since 1999.
13 of the studies testing trastuzumab deruxtecan in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05950945Phase 3Daiichi SankyoTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | 2027-10-01 |
| NCT06048718MedSIRT-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases | 2026-11 |
| NCT04553770Jonsson Comprehensive Cancer CenterTrastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | 2026-12-31 |
| NCT06486883MedSIRSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype | 2027-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, from their registry updates:
Among Daiichi Sankyo’s 24 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a study of trastuzumab deruxtecan for the treatment of HER2-positive unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens.
Participants will receive this study drug along with a cancer drug, an immune checkpoint inhibitor, anti-PD1, called nivolumab.
The study will be done in two parts:
The purpose of this phase 1b (Part 1, Part 2) study is to assess the combination of a test drug (trastuzumab deruxtecan) with nivolumab in participants with HER2-expressing breast and urothelial cancer who had disease progression during or after prior therapies, did not respond to standard therapies, or for whom no standard therapy is available.
The study will be performed in 2 parts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with HER2-expressing breast cancer who received starting intravenous dose of trastuzumab deruxtecan at 3.2 mg/kg and a fixed intravenous dose of 360mg of nivolumab every 3 weeks (Q3W). Escalating/de-escalating doses of trastuzumab deruxtecan in combination with a flat dose of nivolumab was administered on Day 1 of each 21-day cycle. The DLT observation period will be the first 2 cycles.
Drug: Trastuzumab deruxtecan · Drug: Nivolumab
Participants with HER2-expressing breast cancer who received starting intravenous dose of trastuzumab deruxtecan at 3.2 mg/kg and a fixed intravenous dose of 360mg of nivolumab every 3 weeks (Q3W). Escalating/de-escalating doses of trastuzumab deruxtecan in combination with a flat dose of nivolumab was administered on Day 1 of each 21-day cycle. The DLT observation period will be the first 2 cycles.
Drug: Trastuzumab deruxtecan · Drug: Nivolumab
Cohort 1: Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined positive HER2 expression (IHC 3+ or IHC 2+/ISH+) \[as defined by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines\]. These participants received prior ado-trastuzumab emtansine (T-DM1). Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.
Drug: Trastuzumab deruxtecan · Drug: Nivolumab
Cohort 2: Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined low HER2 expression (IHC 1+ or IHC 2+/ISH-), who have exhausted treatments that can confer any clinically meaningful benefit (eg, other therapies such as hormonal therapy for patients who are hormone receptor positive). Participants received the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.
Drug: Trastuzumab deruxtecan · Drug: Nivolumab
Cohort 3: Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 2+ or 3+, who received prior platinum-based therapy with documented progression. Participants received the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.
Drug: Trastuzumab deruxtecan · Drug: Nivolumab
Cohort 4: Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 1+, who received prior platinum-based therapy with documented progression. Participants received the RDE of trastuzumab deruxtecan and the flat dose of nivolumab.
Drug: Trastuzumab deruxtecan · Drug: Nivolumab
The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.
Also known as: Enhertu®, T-DXd
Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.
Also known as: Opdivo®
Number of Participants With Dose-Limiting Toxicities at 3.2 mg/kg and 5.4 mg/kg Dose Level in Participants With HER2-expressing Advanced Breast Cancer in Dose Escalation
A Dose-Limiting Toxicity (DLT) is defined as any Treatment Emergent Adverse Event not attributable to disease or disease-related processes that occurs during the DLT evaluation period (2 complete cycles during Part 1) and is Grade 3 or above according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Each cycle is 21 days. Low dose was set at 3.2 mg/kg and high dose was set at 5.4 mg/kg.
Time frame: Cycles 1 and 2 (each cycle is 21 days)
Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer
The Objective Response Rate (ORR) was the defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by independent central review (ICR) committee based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on ICR is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).
Time frame: Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 2 years 11.5 months (each cycle is 21 days)
Duration of Response (DoR) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer
Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. DoR in participants with confirmed CR/PR based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).
Time frame: Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 5 years (each cycle is 21 days)
Percentage of Participants With Disease Control Rate (DCR) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer
Disease Control Rate (DCR) was defined as the percentage of participants who achieved a best overall response of CR, PR, or stable disease (SD) during study treatment. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and SD as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Confirmation of CR/PR was required. DCR based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).
Time frame: Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 5 years (each cycle is 21 days)
Progression-Free Survival (PFS) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer
Progression-free survival (PFS) was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. PFS based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).
Time frame: Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 5 years (each cycle is 21 days)
Time to Response (TTR) Based on Independent Central Review in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer
Time to response (TTR) is defined as the time from the date of first dose of study treatment to the date of the first documented objective response (CR or PR). CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmation of CR/PR was required. TTR based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).
Time frame: Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 5 years (each cycle is 21 days)
Overall Survival (OS) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer
Overall survival (OS) was defined as the time from the date of first dose of study drug to the date of death due to any cause. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).
Time frame: Date of first dose of study drug to the date of death due to any cause, up to 5 years
Percentage of Participants With Objective Response Rate (ORR) Based on Investigator Assessment in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer
The Objective Response Rate (ORR) was the defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by investigator assessment (IA) based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on IA is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).
Time frame: Every 6 weeks in the first year after Day 1 of Cycle 1 and thereafter every 12 weeks until disease progression or initiation of additional anticancer therapy and survival, up to 5 years (each cycle is 21 days)
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
A treatment-emergent adverse event (TEAE) was defined as an AE that occurred, having been absent before the first dose of study drug, or had worsened in severity or seriousness after initiating the study drug until 47 days after last dose of study drug.
Time frame: Date of signing the informed consent form up to 100 days after last dose of study drug or start of a new anticancer drug (whichever occurs first), up to 5 years
A total of 86 participants were enrolled and treated at 21 study sites in US and Europe. Final study results are reported for all outcome measures.
| Milestone | Dose Escalation (3.2 mg/kg) | Dose Escalation (5.4 mg/kg) | Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC | Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC | Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC |
|---|---|---|---|---|---|---|
| Started | 4 | 3 | 0 | 0 | 0 | 0 |
| Completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Clinical progression | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Dose Escalation (3.2 mg/kg) | Dose Escalation (5.4 mg/kg) | Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC | Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC | Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 29 | 16 | 30 | 4 |
| Completed | 0 | 0 | 6 | 1 | 4 | 0 |
| Not completed | 0 | 0 | 23 | 15 | 26 | 4 |
| Withdrew: Progressive disease | 0 | 0 | 9 | 11 | 15 | 2 |
| Withdrew: Clinical progression | 0 | 0 | 2 | 2 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 10 | 1 | 5 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Miscellaneous | 0 | 0 | 0 | 0 | 3 | 0 |
A Dose-Limiting Toxicity (DLT) is defined as any Treatment Emergent Adverse Event not attributable to disease or disease-related processes that occurs during the DLT evaluation period (2 complete cycles during Part 1) and is Grade 3 or above according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Each cycle is 21 days. Low dose was set at 3.2 mg/kg and high dose was set at 5.4 mg/kg.
| Participants | Dose Escalation (3.2 mg/kg) | Dose Escalation (5.4 mg/kg) |
|---|---|---|
| Number of Participants With Dose-Limiting Toxicities at 3.2 mg/kg and 5.4 mg/kg Dose Level in Participants With HER2-expressing Advanced Breast Cancer in Dose Escalation | 0 | 0 |
The Objective Response Rate (ORR) was the defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by independent central review (ICR) committee based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on ICR is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).
| Percentage of Participants | Dose Escalation (3.2 mg/kg) | Dose Escalation (5.4 mg/kg) + Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC | Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC | Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC |
|---|---|---|---|---|---|
| Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer | 25.0 (NA to NA) | 65.6 (46.8 to 81.4) | 50.0 (24.7 to 75.3) | 36.7 (19.9 to 56.1) | 50.0 (NA to NA) |
Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. DoR in participants with confirmed CR/PR based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).
| months | Dose Escalation (3.2 mg/kg) | Dose Escalation (5.4 mg/kg) + Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC | Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC | Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC |
|---|---|---|---|---|---|
| Independent Central Review | — | NA (7.9 to NA) | 5.5 (2.8 to 8.0) | 13.1 (4.1 to NA) | NA (NA to NA) |
| Investigator Assessment | — | 20.2 (10.4 to NA) | 5.8 (5.2 to 10.4) | 8.7 (2.8 to NA) | NA (NA to NA) |
Disease Control Rate (DCR) was defined as the percentage of participants who achieved a best overall response of CR, PR, or stable disease (SD) during study treatment. CR was defined as a disappearance of all target lesions, PR as at least a 30% decrease in the sum of diameters of target lesions, and SD as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Confirmation of CR/PR was required. DCR based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).
| Percentage of Participants | Dose Escalation (3.2 mg/kg) | Dose Escalation (5.4 mg/kg) + Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC | Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC | Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC |
|---|---|---|---|---|---|
| Independent Central Review | 50 (NA to NA) | 93.8 (79.2 to 99.2) | 75.0 (47.6 to 92.7) | 76.7 (57.7 to 90.1) | 75.0 (NA to NA) |
| Investigator Assessment | 50 (NA to NA) | 93.8 (79.2 to 99.2) | 87.5 (61.7 to 98.4) | 73.3 (54.1 to 87.7) | 50 (NA to NA) |
Progression-free survival (PFS) was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. PFS based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).
| months | Dose Escalation (3.2 mg/kg) | Dose Escalation (5.4 mg/kg) + Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC | Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC | Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC |
|---|---|---|---|---|---|
| Independent Central Review | — | 11.6 (6.9 to NA) | 7.0 (2.3 to 10.8) | 6.9 (2.7 to 14.4) | NA (NA to NA) |
| Investigator Assessment | — | 18.0 (11.0 to NA) | 7.8 (2.4 to 9.8) | 5.5 (2.7 to 8.5) | NA (NA to NA) |
Time to response (TTR) is defined as the time from the date of first dose of study treatment to the date of the first documented objective response (CR or PR). CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmation of CR/PR was required. TTR based on independent central review and investigator assessment is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).
| months | Dose Escalation (3.2 mg/kg) | Dose Escalation (5.4 mg/kg) + Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC | Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC | Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC |
|---|---|---|---|---|---|
| Time to Response (TTR) Based on Independent Central Review in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer | 1.41 (1.41 to 1.41) | 1.61 (1.2 to 5.5) | 3.73 (2.6 to 9.8) | 1.87 (1.2 to 6.9) | 3.25 (1.2 to 5.3) |
Overall survival (OS) was defined as the time from the date of first dose of study drug to the date of death due to any cause. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).
| months | Dose Escalation (3.2 kg/mg) | Dose Escalation (5.4 mg/kg) + Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC | Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC | Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC |
|---|---|---|---|---|---|
| Overall Survival (OS) in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer | NA (NA to NA) | NA (20.8 to NA) | 19.5 (2.7 to NA) | 11.0 (7.2 to NA) | NA (NA to NA) |
The Objective Response Rate (ORR) was the defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by investigator assessment (IA) based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on IA is reported. As prespecified in the protocol, participants enrolled in Part 1 were pooled according to their trastuzumab deruxtecan dose and HER2 expressing levels (HER2 positive or HER2 low) for efficacy analyses. Participants who were dosed at 5.4 mg/kg of trastuzumab deruxtecan and have HER2-positive expression Breast Cancer (IHC score 3+ or IHC score 2+/ISH+) in Part 1 were pooled with the same participants from Part 2 (in this case, participants enrolled in Cohort 1).
| Percentage of Participants | Dose Escalation (3.2 kg/mg) | Dose Escalation (5.4 mg/kg) + Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC | Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC | Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC |
|---|---|---|---|---|---|
| Percentage of Participants With Objective Response Rate (ORR) Based on Investigator Assessment in Participants With HER2-expressing Advanced Breast Cancer or Urothelial Cancer | 25 (NA to NA) | 71.9 (53.3 to 86.3) | 43.8 (19.8 to 70.1) | 40.0 (22.7 to 59.4) | 25.0 (NA to NA) |
A treatment-emergent adverse event (TEAE) was defined as an AE that occurred, having been absent before the first dose of study drug, or had worsened in severity or seriousness after initiating the study drug until 47 days after last dose of study drug.
| Participants | Dose Escalation (3.2 mg/kg) | Dose Escalation (5.4 mg/kg) | Dose Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC | Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC | Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 4 | 3 | 29 | 16 | 30 | 4 |
Collected over Adverse events (AE) were collected from the date of signing the informed consent form up to 100 days after last dose of the study drug, up 5 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation (3.4 mg/kg) | 2/4 (50%) | 3/4 (75%) | 4/4 (100%) |
| Dose Escalation (5.4 mg/kg) | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Dose Expansion Cohort 1: HER2 Positive BC | 7/29 (24.1%) | 12/29 (41.4%) | 29/29 (100%) |
| Dose Expansion Cohort 2: HER2 Low BC | 8/16 (50%) | 4/16 (25%) | 16/16 (100%) |
| Dose Expansion Cohort 3: HER2 High Expressing (IHC 2+/3+) UC | 17/30 (56.7%) | 17/30 (56.7%) | 30/30 (100%) |
| Dose Expansion Cohort 4: HER2 Low Expressing (IHC 1+) UC | 0/4 (0%) | 3/4 (75%) | 4/4 (100%) |
| Event | Dose Escalation (3.4 mg/kg) | Dose Escalation (5.4 mg/kg) | Dose Expansion Cohort 1: HER2 Positive BC | Dose Expansion Cohort 2: HER2 Low BC | Dose Expansion Cohort 3: HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4: HER2 Low Expressing (IHC 1+) UC |
|---|---|---|---|---|---|---|
| Disease ProgressionGeneral disorders | 0/4 | 1/3 | 1/29 | 1/16 | 2/30 | 0/4 |
| PneumothoraxInjury, poisoning and procedural complications | 0/4 | 1/3 | 0/29 | 0/16 | 0/30 | 0/4 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/4 | 0/3 | 1/29 | 0/16 | 2/30 | 1/4 |
| PneumoniaInfections and infestations | 1/4 | 0/3 | 1/29 | 0/16 | 1/30 | 0/4 |
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 0/3 | 0/29 | 0/16 | 0/30 | 1/4 |
| PyelonephritisInfections and infestations | 0/4 | 0/3 | 0/29 | 0/16 | 0/30 | 1/4 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/4 | 0/3 | 0/29 | 0/16 | 0/30 | 1/4 |
| Abdominal painGastrointestinal disorders | 1/4 | 0/3 | 0/29 | 0/16 | 0/30 | 0/4 |
| Bile duct obstructionHepatobiliary disorders | 1/4 | 0/3 | 0/29 | 0/16 | 0/30 | 0/4 |
| DehydrationMetabolism and nutrition disorders | 1/4 | 0/3 | 0/29 | 0/16 | 0/30 | 0/4 |
| Event | Dose Escalation (3.4 mg/kg) | Dose Escalation (5.4 mg/kg) | Dose Expansion Cohort 1: HER2 Positive BC | Dose Expansion Cohort 2: HER2 Low BC | Dose Expansion Cohort 3: HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4: HER2 Low Expressing (IHC 1+) UC |
|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 1/4 | 3/3 | 14/29 | 6/16 | 16/30 | 2/4 |
| NauseaGastrointestinal disorders | 2/4 | 1/3 | 16/29 | 10/16 | 22/30 | 3/4 |
| Oedema PeripheralGeneral disorders | 3/4 | 2/3 | 6/29 | 2/16 | 5/30 | 0/4 |
| Dry MouthGastrointestinal disorders | 3/4 | 0/3 | 1/29 | 2/16 | 2/30 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 2/3 | 11/29 | 6/16 | 13/30 | 0/4 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/4 | 2/3 | 13/29 | 6/16 | 2/30 | 0/4 |
| VomitingGastrointestinal disorders | 1/4 | 1/3 | 9/29 | 8/16 | 14/30 | 1/4 |
| AnaemiaBlood and lymphatic system disorders | 1/4 | 0/3 | 11/29 | 8/16 | 8/30 | 2/4 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/4 | 0/3 | 4/29 | 1/16 | 4/30 | 2/4 |
| HypokalaemiaMetabolism and nutrition disorders | 2/4 | 0/3 | 6/29 | 0/16 | 3/30 | 1/4 |
Baseline characteristics were assessed using the Full Analysis Set.
| Age, Categorical(Participants) | Dose Escalation (3.2 mg/kg) | Dose Escalation (5.4 mg/kg) | Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC | Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC | Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 1 | 24 | 16 | 8 | 2 | 53 |
| >=65 years | 2 | 2 | 5 | 0 | 22 | 2 | 33 |
| Age, Continuous(years) | Dose Escalation (3.2 mg/kg) | Dose Escalation (5.4 mg/kg) | Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC | Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC | Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC | Total |
|---|---|---|---|---|---|---|---|
| Mean | 60.73 ± 10.978 | 63.99 ± 16.995 | 56.37 ± 9.799 | 48.11 ± 8.781 | 69.29 ± 10.352 | 59.71 ± 13.308 | 59.48 ± 12.672 |
| Sex: Female, Male(Participants) | Dose Escalation (3.2 mg/kg) | Dose Escalation (5.4 mg/kg) | Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC | Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC | Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 3 | 29 | 16 | 27 | 3 | 82 |
| Male | 0 | 0 | 0 | 0 | 3 | 1 | 4 |
| Race (NIH/OMB)(Participants) | Dose Escalation (3.2 mg/kg) | Dose Escalation (5.4 mg/kg) | Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC | Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC | Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 5 | 0 | 0 | 0 | 6 |
| White | 3 | 3 | 23 | 14 | 28 | 4 | 75 |
| More than one race | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Dose Escalation (3.2 mg/kg) | Dose Escalation (5.4 mg/kg) | Expansion Cohort 1 (5.4 mg/kg): HER2 Positive BC | Dose Expansion Cohort 2 (5.4 mg/kg): HER2 Low BC | Dose Expansion Cohort 3 (5.4 mg/kg): HER2 High Expressing (IHC 2+/3+) UC | Dose Expansion Cohort 4 (5.4 mg/kg): HER2 Low Expressing (IHC 1+) UC | Total |
|---|---|---|---|---|---|---|---|
| Belgium | 0 | 0 | 2 | 0 | 3 | 2 | 7 |
| United States | 4 | 3 | 17 | 7 | 7 | 0 | 38 |
| Italy | 0 | 0 | 3 | 1 | 7 | 1 | 12 |
| United Kingdom | 0 | 0 | 3 | 1 | 1 | 0 | 5 |
| France | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
| Germany | 0 | 0 | 0 | 0 | 4 | 1 | 5 |
| Spain | 0 | 0 | 4 | 7 | 6 | 0 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
Ran from Aug 2018 to primary completion in Jul 2021, 35 months.
Results were first posted in Jan 2025, 3 years 6 months after primary completion.
Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 35 months is below that.
Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab deruxtecan